Kodiak Sciences' Phase 3 DAYBREAK trial data for Zenkuda in wet AMD demonstrated non-inferior vision gains compared to Regeneron's Eylea, with potential for extended dosing. This positive data for Kodiak creates competitive pressure for Regeneron's blockbuster drug, leading to a negative market reaction for REGN stock.
Kodiak Sciences announced positive Phase 3 data for its wAMD drug, Zenkuda, showing non-inferiority to Regeneron's Eylea, a major revenue driver for REGN. This is significant because Zenkuda also demonstrated the potential for a six-month dosing schedule, which could be a competitive advantage over Eylea's current dosing. This development directly impacts Regeneron's market share and future revenue projections for Eylea, leading to a negative short-term reaction for REGN stock. For Kodiak, this represents a major opportunity to enter a lucrative market, potentially driving its stock higher. Traders should watch for further details on Zenkuda's regulatory pathway and market adoption.